Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Insider filings

<< Previous

Bullboard Posts

Next >>

Post by Mole101on Mar 03, 2021 10:08pm

428 Views

Post# 32712057

Insider filings

2021-03-0317:20 2021-03-01	$ATE	Vaughan, David James 5 - Senior Officer of Issuer Direct Ownership	Common Shares 11 - Acquisition or disposition carried out privately	$8,977 +1,697 vol $5.29 each	8,528
2021-03-0317:17 2021-03-01	$ATE	Wilson, Alain 5 - Senior Officer of Issuer Holder: The Elegen Group Inc. (Control or Direction)	Common Shares 11 - Acquisition or disposition carried out privately	$21,128 +3,994 vol $5.29 each	11,525
2021-03-0317:13 2021-03-01	$ATE	Legault, Daniel Marcel 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Holder: Schmed Enterprises Inc. (Control or Direction)	Common Shares 11 - Acquisition or disposition carried out privately	$116,210 +21,968vol $5.29 each	72,096
2021-03-0317:12 2021-03-01	$ATE	Legault, Daniel Marcel 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Common Shares 11 - Acquisition or disposition carried out privately	$457,987 +86,576vol $5.29 each	204,714
2021-03-0317:08 2021-03-01	$ATE	Wallace, John Lawrence 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Direct Ownership	Common Shares 11 - Acquisition or disposition carried out privately	$765,775 +144,759vol $5.29 each	314,416
2021-03-0317:07 2021-03-01	$ATE	Wallace, John Lawrence 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Holder: AltaPharm International Inc. (Control or Direction)	Common Shares 11 - Acquisition or disposition carried out privately